Payment overview · 2025
General Payments
$1,607.60
17 reported records · 9 companies
Healthcare provider profile · identity verified
Robin Pingeton, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CUMMING, GA · NPI 1154465425
Verified facts
What the public records show
CMS Open Payments records show Robin Pingeton, FNP received $1,607.60 in general payments during 2025 across 17 reported records.
Alpha Cognition USA, Inc. accounted for 18.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $300.85 | 18.7% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $290.28 | 18.1% | 3 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $282.29 | 17.6% | 2 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $183.30 | 11.4% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $136.15 | 8.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $119.86 | 7.5% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $109.91 | 6.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $108.59 | 6.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $76.37 | 4.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,492.22 | 16 |
| Honoraria | $115.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $300.85 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $290.28 | 3 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $282.29 | 2 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $183.30 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $119.86 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $108.59 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $76.37 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 848 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 723 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 639 | 101 |
| Donepezil Hcl | Donepezil Hcl | 620 | 87 |
| Memantine Hcl | Memantine Hcl | 617 | 83 |
| Sertraline Hcl | Sertraline Hcl | 533 | 75 |
| Eliquis | Apixaban | 513 | 83 |
| Losartan Potassium | Losartan Potassium | 482 | 66 |
| Quetiapine Fumarate | Quetiapine Fumarate | 463 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 460 | 70 |
| Mirtazapine | Mirtazapine | 455 | 77 |
| Furosemide | Furosemide | 397 | 69 |
| Potassium Chloride | Potassium Chloride | 395 | 62 |
| Gabapentin | Gabapentin | 382 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 352 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 283 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 257 | 45 |
| Carvedilol | Carvedilol | 242 | 45 |
| Lisinopril | Lisinopril | 240 | 47 |
| Spironolactone | Spironolactone | 236 | 33 |
| Omeprazole | Omeprazole | 233 | 35 |
| Olanzapine | Olanzapine | 228 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 227 | 35 |
| Tramadol Hcl | Tramadol Hcl | 209 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 207 | 36 |
| Risperidone | Risperidone | 207 | 33 |
| Trazodone Hcl | Trazodone Hcl | 196 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 168 | 29 |
| Metformin Hcl | Metformin Hcl | 167 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 160 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 160 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 158 | 23 |
| Ezetimibe | Ezetimibe | 157 | 24 |
| Simvastatin | Simvastatin | 150 | 22 |
| Meloxicam | Meloxicam | 149 | 30 |
| Jardiance | Empagliflozin | 142 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 136 | 24 |
| Montelukast Sodium | Montelukast Sodium | 135 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 133 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 132 | 22 |
| Allopurinol | Allopurinol | 125 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 120 | 95 |
| Finasteride | Finasteride | 118 | 16 |
| Valsartan | Valsartan | 107 | 15 |
| Lorazepam | Lorazepam | 101 | 46 |
| Bupropion Xl | Bupropion Hcl | 95 | 13 |
| Divalproex Sodium | Divalproex Sodium | 94 | 22 |
| Xarelto | Rivaroxaban | 93 | 17 |
| Digoxin | Digoxin | 92 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 89 | 16 |
| Torsemide | Torsemide | 87 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 69 |
| Latanoprost | Latanoprost | 83 | 19 |
| Myrbetriq | Mirabegron | 82 | 14 |
| Alendronate Sodium | Alendronate Sodium | 78 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 78 | 11 |
| Alprazolam | Alprazolam | 76 | 21 |
| Januvia | Sitagliptin Phosphate | 76 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 73 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 72 | suppressed |
| Famotidine | Famotidine | 71 | 18 |
| Glimepiride | Glimepiride | 70 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 70 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 64 | 13 |
| Propranolol Hcl | Propranolol Hcl | 63 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 62 | 14 |
| Levetiracetam | Levetiracetam | 62 | 11 |
| Lamotrigine | Lamotrigine | 60 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 58 | suppressed |
| Methylprednisolone | Methylprednisolone | 57 | 50 |
| Lovastatin | Lovastatin | 55 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 54 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 53 | suppressed |
| Pregabalin | Pregabalin | 53 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 52 | 15 |
| Clonazepam | Clonazepam | 52 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 21 |
| Gemtesa | Vibegron | 52 | 12 |
| Entresto | Sacubitril/Valsartan | 50 | suppressed |
| Nifedipine Er | Nifedipine | 50 | suppressed |
| Ramipril | Ramipril | 48 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 47 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 46 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Folic Acid | Folic Acid | 44 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 36 |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Verapamil Er | Verapamil Hcl | 40 | suppressed |
| Glipizide | Glipizide | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 17 |
| Nystatin | Nystatin | 37 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Lactulose | Lactulose | 36 | suppressed |
| Timolol Maleate | Timolol Maleate | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Brilinta | Ticagrelor | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Prednisone | Prednisone | 30 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | 16 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Galantamine Er | Galantamine Hbr | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Permethrin | Permethrin | 12 | 12 |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pindolol | Pindolol | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,607.60 · 17 records | Alpha Cognition USA, Inc. | Auvelity, Dyanavel XR, FUROSCIX, REXULTI, TZIELD, ZORYVE, Zunveyl | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error